Foundry Partners LLC Sells 3,105 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Foundry Partners LLC lowered its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 51.1% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 2,970 shares of the medical equipment provider’s stock after selling 3,105 shares during the period. Foundry Partners LLC’s holdings in Lantheus were worth $326,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in LNTH. Landscape Capital Management L.L.C. bought a new position in Lantheus in the third quarter worth $435,000. Intech Investment Management LLC lifted its holdings in shares of Lantheus by 219.4% during the 3rd quarter. Intech Investment Management LLC now owns 49,131 shares of the medical equipment provider’s stock worth $5,392,000 after acquiring an additional 33,747 shares during the period. Jennison Associates LLC acquired a new stake in shares of Lantheus during the 3rd quarter valued at about $980,000. Premier Fund Managers Ltd bought a new stake in Lantheus in the third quarter valued at about $693,000. Finally, PNC Financial Services Group Inc. raised its position in Lantheus by 16.6% in the third quarter. PNC Financial Services Group Inc. now owns 9,021 shares of the medical equipment provider’s stock worth $990,000 after purchasing an additional 1,286 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Trading Up 3.7 %

LNTH opened at $90.52 on Friday. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89. The firm has a 50-day moving average price of $103.43 and a two-hundred day moving average price of $96.53. The stock has a market capitalization of $6.29 billion, a PE ratio of 15.06 and a beta of 0.51.

Analyst Ratings Changes

A number of research firms have weighed in on LNTH. JMP Securities decreased their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday, November 7th. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday. Truist Financial reiterated a “buy” rating and set a $120.00 price objective (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, Redburn Atlantic assumed coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price on the stock. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Lantheus has an average rating of “Moderate Buy” and a consensus target price of $122.50.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.